Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 15:371:278-286.
doi: 10.1016/j.ijcard.2022.09.036. Epub 2022 Sep 18.

Does a standard myectomy exist for obstructive hypertrophic cardiomyopathy? From the Morrow variations to precision surgery

Affiliations
Review

Does a standard myectomy exist for obstructive hypertrophic cardiomyopathy? From the Morrow variations to precision surgery

Pierluigi Stefàno et al. Int J Cardiol. .

Abstract

Objectives: The purpose of this work is to revisit the history of surgical treatment for obstructive hypertrophic cardiomyopathy (oHCM) over the last 60 years, in the light of advancing knowledge of the pathophysiology of obstruction.

Methods: In this narrative review the contribution of the different surgical approaches to the field will be assessed in our personal experience in Florence.

Results: Septal myectomy is the treatment of choice in patients with obstructive hypertrophic cardiomyopathy who remain symptomatic despite optimal medical treatment. Over the decades, numerous "theme variations" of the Morrow operation have been proposed, each of them targeting a specific pathophysiological determinant of left ventricular outflow tract obstruction.

Conclusions: Precision surgery in oHCM patients today depends on the ability of the surgeon to combine and master these variations, with the bird's eye view allowed by climbing on the shoulders of giants.

Keywords: Hypertrophic cardiomyopathy; Precision surgery; Septal myectomy.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest Prof. Olivotto has received research grants from BMS-Myokardia, Cytokinetics, Boston Scientific, Sanofi Genzyme, Shire Takeda, Amicus, Menarini International, Bayer. Advisory board, speaker's fees from BMS-Myokardia, Cytokinetics, Sanofi Genzyme, Amicus, Tenaya, Rocket Pharma.

MeSH terms

LinkOut - more resources